journal
MENU ▼
Read by QxMD icon Read
search

Diabetes, Obesity & Metabolism

journal
https://www.readbyqxmd.com/read/28230324/effects-of-short-term-energy-restriction-on-liver-lipid-content-and-inflammatory-status-in-severely-obese-adults-results-of-a-randomised-controlled-trial-rct-using-two-dietary-approaches
#1
Emma L Baldry, Guruprasad P Aithal, Philip Kaye, Iskandar R Idris, Andrew Bennett, Paul C Leeder, Ian A Macdonald
Short-term very low energy diets (VLED) are used in clinical practice prior to bariatric surgery, however, regimens vary and outcomes for a short intervention are unclear. We examined the effect of two VLEDs; a food-based diet (FD) and meal replacement plan (MRP) (LighterLife) over two weeks in a randomised controlled trial (RCT). We collected clinical and anthropometric data, fasting blood samples, and dietary evaluation questionnaires. Surgeons took liver biopsies and made a visual assessment of the liver...
February 23, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28230322/comparative-effectiveness-and-safety-of-different-basal-insulins-in-a-real-world-setting
#2
Linong Ji, Puhong Zhang, Dongshan Zhu, Juming Lu, Xiaohui Guo, Yangfeng Wu, Xian Li, Jiachao Ji, Weiping Jia, Wenying Yang, Dajin Zou, Zhiguang Zhou, Yan Gao, Satish K Garg, Changyu Pan, Jianping Weng, Sanjoy K Paul
AIMS: To compare glucose control and safety of different basal insulin (BI, including Insulin NPH, glargine and detemir) therapies in real-life clinical settings based on a large-scale registry study. METHODS: In this multi-center 6-month prospective observational study, patients with type 2 diabetes uncontrolled (HbA1c≥7%) by oral anti-diabetic drugs (OADs) and willing to initiate BI were enrolled from 209 hospitals of eight regions of China. Type and dose of BI were at the physician's discretion and patients' willingness...
February 23, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28230312/five-year-cost-effectiveness-of-patient-empowerment-programme-pep-for-type-2-diabetes-mellitus-in-primary-care
#3
J X Lian, Sarah M McGhee, C So, J Chau, Carlos Kh Wong, William Cw Wong, Cindy Lk Lam
This study evaluated the short-term cost-effectiveness of the Patient Empowerment Programme (PEP) for diabetes mellitus in Hong Kong. Propensity score matching was used to select a matched group of PEP and non-PEP subjects. A societal perspective was adopted to estimate the cost of PEP. The outcome measures were the cumulative incidence of all-cause mortality and diabetic complication over a five-year follow-up and the number needed to treat (NNT) to avoid one event. The incremental cost-effectiveness ratio (ICER) of cost per event avoided was calculated using the PEP cost per subject multiplied by the NNT...
February 23, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28218819/healthcare-resource-utilization-and-related-financial-costs-associated-with-glucose-lowering-with-either-exenatide-or-basal-insulin-a-retrospective-cohort-study
#4
Sarah E Holden, Christopher Ll Morgan, Qing Qiao, Sara Jenkins-Jones, Ellen R Berni, Craig J Currie
AIMS: Type 2 diabetes is a major health problem placing increasing demands on healthcare systems. Our objective was to estimate healthcare resource use and related financial costs following treatment with exenatide-based regimens prescribed as once-weekly (EQW) or twice-daily (EBID) formulations, compared with regimens based on basal insulin (BI). MATERIALS AND METHODS: This retrospective cohort study used data from the UK Clinical Practice Research Datalink (CPRD) linked to Hospital Episode Statistics (HES)...
February 20, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28211632/amp-activated-protein-kinase-activator-a-769662-increases-intracellular-calcium-and-atp-release-from-astrocytes-in-an-ampk-independent-manner
#5
Julia M Vlachaki Walker, Josephine L Robb, Ana M Cruz, Amrinder Malhi, Paul G Weightman Potter, Michael L J Ashford, Rory J McCrimmon, Kate L J Ellacott, Craig Beall
AIM: Astrocytes are the main sources of extracellular ATP (eATP) within the brain, which functions as a gliotransmitter, capable of modulating neuronal and astrocytic activity. These cells play an important role in regulating energy homeostasis partly via astrocyte-derived ATP. Given the role of AMPK in regulating intracellular ATP levels, we hypothesised that AMPK may alter ATP release from astrocytes. METHODS: Measurements of ATP release were made from human U373 astrocytoma cells, primary mouse hypothalamic (HTAS) and cortical astrocytes (CRTAS) and wild type and AMPK α1/α2 null mouse embryonic fibroblasts (MEFs)...
February 17, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28211611/short-acting-glp-1-receptor-agonists-as-add-on-to-insulin-therapy-in-type-1-diabetes-a-review
#6
REVIEW
Anders Albèr, Andreas Brønden, Filip K Knop
A large proportion of patients with type 1 diabetes do not reach their glycemic target of glycated hemoglobin (HbA1c) <7.0% (53 mmol/mol) and, furthermore, an increasing number of patients with type 1 diabetes suffer from overweight and obesity. Treatment of type 1 diabetes is based on insulin therapy with well-described and unfortunate adverse effects such as hypoglycemia and increased body weight. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have received increasing interest as a possible adjunctive treatment to insulin in type 1 diabetes due to their glucagonostatic and extrapancreatic effects...
February 17, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28211609/comparison-of-body-mass-index-at-diagnosis-of-diabetes-in-a-multiethnic-population-a-case-control-study-with-matched-non-diabetic-controls
#7
Sanjoy K Paul, Ebenezer S Owusu Adjah, Mayukh Samanta, Kiran Patel, Srikanth Bellary, Wasim Hanif, Kamlesh Khunti
AIMS: To investigate the probability of developing type 2 diabetes mellitus (T2DM) at different body mass index compared to matched non-diabetic controls in a multi-ethnic population. MATERIALS AND METHODS: Case-control study of 90,367 patients with incident diabetes and 362,548 age-sex-ethnicity matched controls from UK primary care. Probability of developing T2DM was estimated. RESULTS: Case and control patients were 56 years old at index and 56% were male...
February 17, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28211608/preclinical-characterisation-of-55p0251-a-novel-compound-that-amplifies-glucose-stimulated-insulin-secretion-and-counteracts-hyperglycaemia-in-rodents
#8
Karin Stadlbauer, Barbara Brunmair, Zsuzsanna Lehner, Immanuel Adorjan, Thomas Scherer, Anton Luger, Leonhardt Bauer, Clemens Fürnsinn
AIMS: 55P0251 is a novel compound with blood glucose lowering activity in mice, which has been developed from a molecular backbone structure found in herbal remedies. We here report its basic pharmacological attributes and initial progress in unmasking the mode of action. MATERIALS AND METHODS: Pharmacokinetic properties of 55P0251 were portrayed in several species. First efforts to elucidate the glucose lowering mechanism in rodents included numerous experimental protocols dealing with glucose tolerance, insulin secretion from isolated pancreatic islets, and comparison to established drugs...
February 17, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28211604/delays-in-treatment-intensification-with-oral-antidiabetic-drugs-and-risk-of-microvascular-and-macrovascular-events-in-patients-with-poor-glycemic-control-an-individual-patient-simulation-study
#9
Henry J Folse, Jayanti Mukherjee, John J Sheehan, Alexandra J Ward, Ryan L Pelkey, Tuan A Dinh, Lei Qin, Jennifer Kim
AIMS: Despite guideline recommendations, many patients with type 2 diabetes on oral antidiabetic drugs (OADs) whose HbA1c results remain above target do not experience timely treatment intensification. This study uses the Archimedes Model® to estimate the consequences of delays in OAD treatment intensification on glycemic control and long-term outcomes at 5 and 20 years. MATERIALS AND METHODS: Using real world data, we modeled a cohort of hypothetical patients with HbA1c ≥8%, on metformin, with no history of insulin use...
February 17, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28206714/opposite-effects-of-a-glucokinase-activator-and-metformin-on-glucose-regulated-gene-expression-in-hepatocytes
#10
Ziad H Al-Oanzi, Sophia Fountana, Tabassum Moonira, Susan J Tudhope, John L Petrie, Ahmed Alshawi, Gillian Patman, Catherine Arden, Helen L Reeves, Loranne Agius
AIM: Small molecule activators of glucokinase (GKAs) have been extensively explored as potential anti-hyperglycaemic drugs for type 2 diabetes (T2D). Several GKAs were remarkably effective at lowering blood glucose during early therapy but then lost their glycaemic efficacy chronically during clinical trials. We used rat hepatocytes to test the hypothesis that GKAs raise hepatocyte glucose 6-phosphate, (G6P, the glucokinase product) and down-stream metabolites with consequent repression of the liver glucokinase gene (Gck)...
February 16, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28206704/lipid-lowering-efficacy-and-safety-of-alirocumab-in-patients-with-or-without-diabetes-a-sub-analysis-of-odyssey-combo-ii
#11
Lawrence A Leiter, Jose Luis Zamorano, Maja Bujas-Bobanovic, Michael J Louie, Guillaume Lecorps, Christopher P Cannon, Yehuda Handelsman
AIM: This sub-analysis of the ODYSSEY COMBO II study compared the effects of alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in high cardiovascular risk patients with or without diabetes mellitus (DM) receiving maximally tolerated statin therapy. MATERIALS AND METHODS: COMBO II was a 104-week, double-blind study (n = 720) enrolling patients with documented atherosclerotic cardiovascular disease (ASCVD) and baseline LDL-C ≥70 mg/dL (1...
February 16, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28205324/evaluation-of-subcutaneous-glucose-monitoring-systems-under-routine-environmental-conditions-in-patients-with-type-1-diabetes
#12
Felix Aberer, Martin Hajnsek, Markus Rumpler, Sabine Zenz, Petra Baumann, Hesham Elsayed, Adelheid Puffing, Gerlies Treiber, Thomas R Pieber, Harald Sourij, Julia K Mader
: Continuous and flash glucose monitoring (GM) systems have been established in diabetes care. We compared sensor performance of three commercially available GM systems. 12 patients with type 1 diabetes were included in a single-centre, open-label study where sensor performance of Abbott FreeStyle libre (Abbott), Dexcom G4 Platinum (Dexcom) and Medtronic MiniMed 640G (Medtronic) over 12 hours was compared during mimicked real-life conditions (meals, exercise, hypo- and hyperglycaemia)...
February 16, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28205322/efficacy-and-safety-of-autoinjected-exenatide-once-weekly-suspension-versus-sitagliptin-or-placebo-with-metformin-in-patients-with-type-2-diabetes-the-duration-neo-2-randomized-clinical-study
#13
Kishore M Gadde, Marion L Vetter, Nayyar Iqbal, Elise Hardy, Peter Öhman
AIMS: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors treat type 2 diabetes through incretin-signaling pathways. This study compared the efficacy and safety of the glucagon-like peptide-1 receptor agonist exenatide once-weekly (Miglyol) suspension for autoinjection (QWS-AI) with the dipeptidyl peptidase-4 inhibitor sitagliptin or placebo. MATERIALS AND METHODS: In this open-label, multicenter study of patients with type 2 diabetes who had suboptimal glycemic control on metformin monotherapy, 365 patients were randomized to receive exenatide 2...
February 16, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28195389/no-increased-risk-of-cardiovascular-events-in-older-adults-initiating-dipeptidyl-peptidase-4-inhibitors-versus-therapeutic-alternatives
#14
Mugdha Gokhale, John B Buse, Michele Jonsson Funk, Jennifer Lund, Virginia Pate, Ross J Simpson, Til Stürmer
OBJECTIVE: Randomized placebo-controlled trials have examined the cardiovascular (CV) effects of dipeptidyl peptidase-4 inhibitors (DPP-4i), but data on incidence relative to therapeutic alternatives are limited in the older US Medicare population. We compared the CV risk with DPP-4i relative to sulfonylureas (SU) and thiazolidinediones (TZD). METHODS: During 2007-2013, using Medicare beneficiaries >65 years we identified two new-user cohorts without the use of drugs being compared in the 6 months before initiation: DPP-4i versus SU and DPP-4i versus TZD...
February 14, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28195387/baseline-adiponectin-concentration-and-clinical-outcomes-among-patients-with-diabetes-and-recent-acute-coronary-syndrome-in-the-examine-trial
#15
Brian A Bergmark, Christopher P Cannon, William B White, Petr Jarolim, Yuyin Liu, Marc P Bonaca, Faiez Zannad, David A Morrow
INTRODUCTION: Adiponectin is a pleiotropic adipocytokine with a strong inverse (protective) association with obesity, diabetes, and cardiovascular outcomes in stable patients. However, this relationship may be reversed in the setting of acute coronary syndrome (ACS). Given this possible complex relationship, we investigated adiponectin and cardiovascular (CV) outcomes in patients with diabetes and recent ACS. MATERIALS AND METHODS: We analyzed baseline adiponectin concentration and CV outcomes in 5,213 patients with type 2 diabetes enrolled 15-90 days (median 45 days) after ACS in the EXAMINE trial of alogliptin vs placebo...
February 14, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28191913/treatment-with-the-glucagon-receptor-antagonist-ly2409021-increases-ambulatory-blood-pressure-in-patients-with-type-2-diabetes
#16
Christof M Kazda, Juan Frias, Irene Foga, Xuewei Cui, Cristina B Guzman, Parag Garhyan, Cory Heilmann, Jihui Anne Yang, Thomas A Hardy
AIMS: To assess the effect of LY2409021 on systolic blood pressure (SBP) in patients with type 2 diabetes. MATERIALS AND METHODS: This 6-week, randomized, crossover study evaluated the effects of once-daily administration of LY2409021 20 mg vs those of placebo on SBP, diastolic BP (DBP), and mean arterial pressure (MAP) using 24-hour ambulatory BP monitoring (ABPM) in 270 subjects treated with diet/exercise ± metformin. Other measures included changes in glycemic control, serum lipids, and hepatic safety markers...
February 13, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28188972/effect-of-exercise-combined-with-glucagon-like-peptide-1-receptor-agonist-treatment-on-cardiac-function-a-randomised-double-blinded-placebo-controlled-clinical-trial
#17
Peter G Jørgensen, Magnus T Jensen, Pernille Mensberg, Heidi Storgaard, Signe Nyby, Jan S Jensen, Filip K Knop, Tina Vilsbøll
In patients with type 2 diabetes, both supervised exercise and treatment with the glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) liraglutide may improve cardiac function. We evaluated cardiac function before and after 16 weeks of treatment with the GLP-1RA liraglutide or placebo combined with supervised exercise in 33 dysregulated patients with type 2 diabetes on diet and/or metformin. Early diastolic myocardial tissue velocity was improved by exercise in the placebo group (-7.1 ± 1.6 cm/s (mean ± standard deviation) to -7...
February 11, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28181738/a-comparison-of-the-effects-of-diets-high-in-animal-or-plant-protein-on-metabolic-and-cardiovascular-markers-in-type-2-diabetes-a-randomized-clinical-trial
#18
Stephanie Sucher, Mariya Markova, Silke Hornemann, Olga Pivovarova, Natalia Rudovich, Ralph Thomann, Rosemarie Schneeweiss, Sascha Rohn, Andreas F H Pfeiffer
AIMS: High animal protein diets support body weight and glucose control but may induce insulin resistance and type 2 diabetes (T2DM) while plant protein based diets appear to be metabolically advantageous and reduce cardiovascular events. We therefore compared high animal versus plant protein diets differing in amino acid composition in people with T2DM. MATERIALS AND METHODS: We compared isocaloric diets containing 30% of energy (E%) either as animal (AP) or plant (PP) protein, using newly developed plant protein enriched foods, both combined with 30 E% fat and 40 E% carbohydrates in 44 patients with T2DM over six weeks in a randomized parallel group study...
February 9, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28181728/hypoglycemia-manifestations-and-recurrent-events-lessons-from-the-savor-timi-53-outcome-study
#19
Avivit Cahn, Ofri Mosenzon, Deepak L Bhatt, Gil Leibowitz, Ilan Yanuv, Aliza Rozenberg, Nayyar Iqbal, Boaz Hirshberg, Christina Stahre, KyungAh Im, Estella Kanevsky, Itamar Raz
Hypoglycemia is a well-known risk associated with the use of sulfonylureas and insulin, often limiting achievement of glycemic goals. Recognizing the precipitants and recurrence patterns of hypoglycemic events, particularly major events, is therefore clinically important. The SAVOR-TIMI-53 trial was a cardiovascular outcome study of 16,492 patients allocated to saxagliptin vs. placebo added to conventional care for a median of 2.1 years. Hypoglycemic events were a pre-specified outcome in the study and were defined as a symptomatic episode which recovered with carbohydrates or any recorded blood glucose <54 mg/dL...
February 9, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28181725/treatment-patterns-in-patients-with-type-2-diabetes-mellitus-treated-with-glp-1-receptor-agonists-higher-adherence-and-persistence-with-dulaglutide-compared-to-exenatide-qw-and-liraglutide
#20
C Alatorre, L Fernández Landó, M Yu, K Brown, L Montejano, P Juneau, R Mody, R Swindle
AIMS: The overall study aims were to compare adherence (proportion of days covered [PDC]), persistence, and treatment patterns among patients with type 2 diabetes mellitus (T2DM) newly initiating Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs). More specifically, the main objectives were to compare dulaglutide vs. exenatide once weekly (QW) and dulaglutide vs. liraglutide. MATERIALS AND METHODS: T2DM patients newly initiating dulaglutide, albiglutide, exenatide QW, exenatide twice-daily (BID), and liraglutide between November 2014 and April 2015, were hierarchically selected from Truven Health's MarketScan(®) Research Databases...
February 9, 2017: Diabetes, Obesity & Metabolism
journal
journal
34603
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"